Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 1

Interventions

pembrolizumab 86Cyclophosphamide 58Carboplatin 57Specimen Handling 55fludarabine 46Nivolumab 45Magnetic Resonance Spectroscopy 44Gemcitabine 41Biopsy 40Bevacizumab 36venetoclax 32Dexamethasone 32Paclitaxel 29Cisplatin 29Pemetrexed 28Injections 28Docetaxel 26atezolizumab 24Ipilimumab 23Capecitabine 22Temozolomide 21Azacitidine 21Rituximab 20Oxaliplatin 20Cetuximab 20Lenalidomide 19Fulvestrant 19abemaciclib 18Fluorouracil 17Vincristine 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × vocimagene amiretrorepvec × 90 days × Clear all
NCT06504381 2026-03-11

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

University of California, San Francisco

Phase 1/2 Recruiting
70 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡